On August 18, 2019, the final of the "Fifth Beijing Innovation and Entrepreneurship Biomedical and Artificial Intelligence Theme Competition" was held in Changping District, Beijing. Dongfang Baitai attended and won the second prize.

The event was jointly guided by the Torch Center of the Ministry of Science and Technology, the Municipal Science and Technology Commission, the Municipal Development and Reform Commission, the Municipal Education Commission, the Municipal Economic and Information Bureau, the Municipal Finance Bureau, the Municipal Human Resources and Social Affairs Bureau, the Zhongguancun Management Committee, and the Medical and Health Science and Technology Development Research Center of the Health and Health Commission, and hosted by Zhongguancun Life Science Park, Zhongguancun Science and Technology Park Daxing Biomedical Industry Base, Beijing Yizhuang Biomedical Park, Zhongguancun Miyun Park, and Beijing Entrepreneurial Incubation Association. The event is one of the industry competitions of the 8th China Innovation and Entrepreneurship Competition in Beijing. The best project will be selected and recommended to be shortlisted in the Beijing municipal final and the national final through layer by layer selection.

The competition has been open to the public since May. By the end of registration, nearly 100 effective projects in the field of biomedicine had been collected. It involves gene detection, new antibody drugs, AI diagnostic system, tumor detection, surgical robot, etc. After two rounds of strict screening in the preliminary and final rounds, a total of 25 excellent innovation and entrepreneurship projects were qualified for the finals of the theme competition. Beijing Dongfang Baitai Biotechnology Co., Ltd. stands out from the crowd.

Beijing Dongfang Baitai was founded in 2011. The main direction is to develop humanized monoclonal antibodies and therapeutic vaccines. It is a leading high-tech enterprise engaged in innovative antibody R&D and production. Take this award-winning Exendin-4 Fc antibody fusion protein (JY09) as an example.

JY09 is one of the antibody drugs independently developed by Dongfang Baitai. It is a long-term treatment for type II diabetes. The same as insulin requires subcutaneous injection. However, single injection of JY09 can last for 7-14 days. It can control the blood sugar level of the patient smoothly. It reduces the risk of hypoglycemia and greatly ensures the life safety of patients.

And JY09 has the effect of repairing islets and promoting insulin secretion. It has obtained the "triple" project of the national major new drug discovery project, the "priority review" project recommended by the National Health and Family Planning Commission and the Chinese patent authorization. International PCT patents have been granted by the United States, Japan, South Korea, Europe, Eurasia and other countries. Brazil and India have entered the trial stage. At present, it has obtained the clinical approval document approved by the State Food and Drug Administration of China, and is conducting clinical research.

Dongfang Baitai is located in Yizhuang Park, Zhongguancun, Beijing. The company covers an area of nearly 40000 square meters. It has a professional team of hundreds of people. Nearly 20 R&D pipeline layouts have been carried out in tumor, diabetes, autoimmune diseases, etc. It has undertaken a number of national "major new drug development", special projects of ministries and commissions, "863" plan and other key projects during the 11th and 12th Five Year Plan. Dongfang Baitai takes scientific research as its core competitiveness, and integrates R&D and production organically.

The company currently has 1 3 × 3000L mammalian cell large-scale batch culture and purification production line, 1 bacterial/yeast production line and other R&D industrial facilities, and a variety of advanced innovative antibody R&D and production technology platforms.

This event has greatly encouraged Dongfang Baitai to be at the forefront of research and development. Dongfang Baitai will live up to expectations to do the best in antibody drugs. For the majority of patients, provide safe drugs and reassuring drugs. Always work hard for the patients and consider the patients who are tortured by the patients personally.

The highest good is like water. Beijing Dongfang Baitai Biotechnology Co., Ltd. adheres to the concept of "benevolence and benevolence for doctors and conscience for medicine". Through continuous exploration and improvement of independent innovation ability, the company vigorously develops biomedical technology. Especially in cancer and immune diseases, it can help human beings extend their life cycle, improve their quality of life, and protect their healthy lives. Dongfang Baitai will improve the market share and competitiveness of China's antibody drugs in the world's advanced antibody drugs, and make unremitting efforts to establish a biomedical innovative enterprise that attracts global attention!